Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Tianjin Medical University

Status and phase: Suspended; Phase 2

Conditions: Non Small Cell Lung Cancer

Treatments: Drug: gefitinib

Study type: Interventional

Funder types: Other

Identifiers

NCT00986284

TMU-CIH-LCC-001

Details and patient eligibility

About

This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.

Enrollment: 102 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients pathological diagnosed with NSCLC,with EGFR sensitive mutation;
• Stage IIIA patients with technical operable disease evaluated by image and lab results;
• Patients without chemotherapy or targeted-therapy before;
• Inform Consent.

Exclusion criteria

• Patients with malignant tumor other than lung cancer;
• Patients with other diseases such as cardiovascular disease that may hamper follow up;
• Patients that may not coordinate well,judged by researcher.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

102 participants in 1 patient group

Gefitinib, Neoadjuvant therapy

Experimental group

Description:

Patients with EGFR mutation will be recruited and treated with gefitinib.

Treatment:

Drug: gefitinib